These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23895888)

  • 61. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
    Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.
    Suzuki A; Xiao L; Taketa T; Sudo K; Wadhwa R; Blum MA; Skinner H; Komaki R; Weston B; Lee JH; Bhutani MS; Rice DC; Maru DM; Erasmus J; Swisher SG; Hofstetter WL; Ajani JA
    Ann Oncol; 2013 Nov; 24(11):2854-9. PubMed ID: 23994746
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy.
    Ishihara R; Yamamoto S; Iishi H; Nagai K; Matui F; Kawada N; Ohta T; Kanzaki H; Hanafusa M; Hanaoka N; Takeuchi Y; Higashino K; Uedo N; Sugimoto N; Kawaguchi Y; Nishiyama K; Motoori M; Yano M; Hosoki T
    Int J Clin Oncol; 2012 Jun; 17(3):225-32. PubMed ID: 21735356
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy.
    Jones DR; Parker LA; Detterbeck FC; Egan TM
    Cancer; 1999 Mar; 85(5):1026-32. PubMed ID: 10091784
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Is the predictive ability of positron emission tomography after neoadjuvant treatment for esophageal cancer ready for prime-time?
    Groth SS; D'Cunha J
    Semin Thorac Cardiovasc Surg; 2011; 23(2):87-8. PubMed ID: 22041033
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Metformin use and improved response to therapy in esophageal adenocarcinoma.
    Skinner HD; McCurdy MR; Echeverria AE; Lin SH; Welsh JW; O'Reilly MS; Hofstetter WL; Ajani JA; Komaki R; Cox JD; Sandulache VC; Myers JN; Guerrero TM
    Acta Oncol; 2013 Jun; 52(5):1002-9. PubMed ID: 22950385
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil.
    Suzuki K; Etoh T; Shibata T; Nishiki K; Fumoto S; Ueda Y; Shiroshita H; Shiraishi N; Inomata M
    World J Clin Oncol; 2021 Apr; 12(4):249-261. PubMed ID: 33959478
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.
    Cheedella NK; Suzuki A; Xiao L; Hofstetter WL; Maru DM; Taketa T; Sudo K; Blum MA; Lin SH; Welch J; Lee JH; Bhutani MS; Rice DC; Vaporciyan AA; Swisher SG; Ajani JA
    Ann Oncol; 2013 May; 24(5):1262-6. PubMed ID: 23247658
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be Delayed.
    Bayley EM; Ivy ML; Shewale JB; Ge PS; Antonoff MB; Francis AM; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Vaporciyan AA; Walsh GL; Lee JJ; Louie BE; Swisher SG
    Ann Surg; 2023 May; 277(5):721-726. PubMed ID: 36052678
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers.
    Walker BS; Sutton TL; Zarour L; Hunter JG; Wood SG; Tsikitis VL; Herzig DO; Lopez CD; Chen EY; Mayo SC; Wong MH
    Ann Surg Oncol; 2021 Dec; 28(13):8567-8578. PubMed ID: 34365557
    [TBL] [Abstract][Full Text] [Related]  

  • 71. (P053) Esophageal Cancer Pathologic Complete Response Rate After Neoadjuvant Chemoradiation: Is There a Difference Between Academic Centers vs Community Centers.
    Oncology (Williston Park); 2015 Apr; 29(4 Suppl 1):. PubMed ID: 25930812
    [No Abstract]   [Full Text] [Related]  

  • 72. Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal cancer.
    Brown LM
    J Thorac Cardiovasc Surg; 2019 Mar; 157(3):1262-1263. PubMed ID: 33198002
    [No Abstract]   [Full Text] [Related]  

  • 73. Pathologic complete response is not equivalent to cure in esophageal cancer.
    Carr R; Molena D
    J Thorac Dis; 2019 Sep; 11(Suppl 15):S2041-S2042. PubMed ID: 31632823
    [No Abstract]   [Full Text] [Related]  

  • 74. Positron emission tomography in esophageal cancer.
    D'Amico TA
    Gastrointest Cancer Res; 2008 Jan; 2(1):35-6. PubMed ID: 19259320
    [No Abstract]   [Full Text] [Related]  

  • 75. Interim position emission tomography-computed tomography during multimodality treatment of locally advanced esophageal cancer: a scoping review.
    Zhu H; Hao S; Tseng I; Shen J; Rivin Del Campo E; Davies A; Segelov E; Liu Q; Chen Y; Song S; Zhao K
    Quant Imaging Med Surg; 2023 Sep; 13(9):6280-6295. PubMed ID: 37711778
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis.
    Wang J; Qin J; Jing S; Liu Q; Cheng Y; Wang Y; Cao F
    Thorac Cancer; 2018 Dec; 9(12):1638-1647. PubMed ID: 30277016
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy.
    Zhang W; Luo Y; Wang X; Han G; Wang P; Yuan W; Dai SB
    Cancer Manag Res; 2018; 10():2675-2682. PubMed ID: 30147366
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Radiotherapy for esophageal carcinoma: dose, response and survival.
    Luo Y; Mao Q; Wang X; Yu J; Li M
    Cancer Manag Res; 2018; 10():13-21. PubMed ID: 29343986
    [TBL] [Abstract][Full Text] [Related]  

  • 79. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer?
    Altorki N; Harrison S
    Ann Cardiothorac Surg; 2017 Mar; 6(2):167-174. PubMed ID: 28447006
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Complete metabolic response is not uniformly predictive of complete pathologic response after induction therapy for esophageal cancer.
    Stiles BM; Salzler G; Jorgensen A; Nasar A; Paul S; Lee PC; Port JL; Altorki NK
    Ann Thorac Surg; 2013 Nov; 96(5):1820-5. PubMed ID: 23895888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.